Thymosin-beta-4 venous-ulcer trial
The effect of thymosin treatment of venous ulcers.
Guarnera G, DeRosa A, Camerini R, 8 European sites. · Annals of the New York Academy of Sciences
Study record
- Population
73 patients with venous stasis ulcers randomized at eight European sites: five in Italy and three in Poland.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Formulation
Topically administered synthetic 43-amino-acid thymosin-beta-4. Exact preparation and all dose-arm details require full text.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Route
Topical ulcer treatment.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Dose & frequency
Abstract highlights a possible 0.03% concentration signal but omits all tested doses, amount and frequency. No human or KLOW regimen established.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Study design
Phase 2 double-blind placebo-controlled dose-escalation trial. Allocation details and analysis populations unavailable in abstract. Linkage to a similarly described registered trial is unverified; its results are not merged with this publication.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Duration
Healing discussed within three months. Exact dosing schedule, stopping rules and later follow-up not available.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Reported findings
Authors suggest 0.03% may accelerate healing, especially smaller or less severe wounds, with approximately 25% complete healing within three months. Abstract omits arm-specific counts and statistical comparisons; this is not an established 25-percentage-point benefit over placebo.
Read source · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Adverse events
Authors describe safety as acceptable and comparable to placebo, but abstract supplies no event counts, severity distribution or ascertainment methods.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable- Monitoring
Ulcer healing and safety evaluated; assessment schedule and measurement methods not extracted.
Inspect extraction gap · Abstract-level extractionPrimary abstract — clinical report; full text unavailable
What it supports
Limited formulation- and indication-specific human evidence.
What it does not establish
Abstract-level report; cannot establish systemic TB-500, peptide pairing, KLOW efficacy or long-term safety. No cross-study dose substitution.
Funding
Not reported in available abstract.
Literature search cutoff: 2026-09-08 · Not independently clinically reviewed
Browse study library